Laverdia®-CA1 is a conditionally approved cancer drug used to treat lymphoma in dogs. The active ingredient in LAVERDIA®-CA1 is verdinexor, a substance that works by preventing tumor suppressing proteins from leaving the nucleus of cells, resulting in disruption of cancer cell survival and eventual cancer cell death.
For a veterinary drug to receive conditional approval, it must be shown to be safe when used according to the label. It must also demonstrate a “reasonable expectation of effectiveness,” but has not yet proven that it meets the “substantial evidence” standard of effectiveness for full approval. While a drug is conditionally approved it is not to be used for any extra-label species or indications.